Protalix BioTherapeutics (PLX) Invested Capital (2010 - 2026)

Protalix BioTherapeutics has reported Invested Capital for 17 years, with the latest figure at $67.2 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 48.71% year-over-year to $67.2 million; the trailing twelve-month figure through Mar 2026 stood at $67.2 million (up 48.71% YoY), and the FY2025 full-year result was $48.2 million, up 11.62% from the prior year.
• Invested Capital for Q1 2026 stood at $67.2 million, up from $48.2 million in the prior quarter.
• The five-year high for Invested Capital was $67.2 million in Q1 2026, with the low at -$11.5 million in Q3 2022.
• Average Invested Capital over 5 years is $32.4 million, with a median of $45.2 million recorded in 2025.
• Year-over-year, Invested Capital slumped 433.55% in 2022 and surged 4880.75% in 2024.
• Tracing PLX's Invested Capital over 5 years: stood at -$10.6 million in 2022, then soared by 605.83% to $53.8 million in 2023, then declined by 19.71% to $43.2 million in 2024, then advanced by 11.62% to $48.2 million in 2025, then surged by 39.39% to $67.2 million in 2026.
• The last three Invested Capital figures came in at $67.2 million (Q1 2026), $48.2 million (Q4 2025), and $52.9 million (Q3 2025), per Business Quant data.

Peer Comparison